当前位置: 首页 > 详情页

Honokiol Alleviates Cognitive Deficits of Alzheimer's Disease (PS1(V97L)) Transgenic Mice by Activating Mitochondrial SIRT3

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [a]Innovation Center for Neurological Disorders, Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, P.R. China [b]Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, P.R. China [c]Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, P.R. China [d]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, P.R. China [e]Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, P.R. China [f]National Clinical Research Center for Geriatric Disorders, Beijing, P.R. China
出处:
ISSN:

关键词: Alzheimer's disease amyloid-beta protein cognitive dysfunction mitochondria sirtuin 3 (SIRT3)

摘要:
Accumulating evidence has demonstrated that mitochondrial dysfunction is a prominent early event in the progression of Alzheimer's disease (AD). Whether protecting mitochondrial function can reduce amyloid-beta oligomer (A beta O)-induced neurotoxicity in PS1(V97L) transgenic mice remains unknown. In this study, we examined the possible protective effects of honokiol (HKL) on mitochondrial dysfunction induced by A beta Os in neurons, and cognitive function in AD PS1(V97L)transgenic mice. We determined that HKL increased mitochondrial sirtuin 3 (SIRT3) expression levels and activity, which in turn markedly improved ATP production and weakened mitochondrial reactive oxygen species production. We demonstrated that the enhanced energy metabolism and attenuated oxidative stress of HKL restores A beta O-mediated mitochondrial dysfunction in vitro and in vivo. Consequently, memory deficits in the PS1(V97L) transgenic mice were rescued by HKL in the early stages. These results suggest that HKL has therapeutic potential for delaying the onset of AD symptoms by alleviating mitochondrial impairment and increasing hyperactivation of SIRT3 in the pathogenesis of preclinical AD.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 2 区 医学
小类 | 3 区 神经科学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 神经科学
JCR分区:
出版当年[2016]版:
Q2 NEUROSCIENCES
最新[2023]版:
Q2 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [a]Innovation Center for Neurological Disorders, Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, P.R. China
通讯作者:
通讯机构: [*1]Innovation Center for Neurological Disorders, XuanWu Hospital, Capital Medical University, Beijing 100053, P.R. China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院